Announcement on 2026 Interest Payment for "Aurisco Convertible Bonds"
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on 2026 Interest Payment for "Aurisco Convertible Bonds"
Filed with SSE · · 5 pages · Chinese
Release
Aurisco Pharmaceutical Co. Ltd. on 6ix
Story so far
- Announcement on Not Revising Downward Conversion Price of ""Aurisco Convertible Bonds"
- Announcement on Adjusting the Conversion Price of "Aurisco Convertible Bonds" Due to Implementation of Dividend Distribution
- Indicative Announcement on ""Aurisco Convertible Bonds"" Expected to Meet Conditions for Revising Conversion Price
Earlier from Aurisco Pharmaceutical
- Announcement on Inclusion of the Company's Main Products in the "National Essential Medicines List (2026 Edition)"
- Announcement on Passing GMP Compliance Inspection for Drugs
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Correction Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
Later from Aurisco Pharmaceutical
- Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
- Announcement on the Wholly-owned Subsidiary Passing the U.S. FDA On-Site Inspection
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned Subsidiary
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- (605116)"Aurisco Pharmaceutical Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
Follow Aurisco Pharmaceutical into a list and get an email when it puts out news.
Follow Aurisco Pharmaceutical